Universal ProbeLibrary based real-time PCR assay for detection and confirmation of human papillomavirus genotype 52 infections

Journal of Virological Methods

Volumn 163, Issue 2, 2010, Pages 492-494

  Kocjan, Boštjan J ^a   Poljak, Mario ^a   Seme, Katja ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Cervical cancer; HPV 52; HPV variants; LightCycler; Real time PCR; TaqMan

Indexed keywords

PLASMID DNA; VIRUS DNA;

ARTICLE; ASSAY; CLINICAL EVALUATION; COMPUTER MODEL; DIAGNOSTIC VALUE; DNA EXTRACTION; DNA PROBE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA; VIRUS DETECTION; VIRUS INFECTION; VIRUS LOAD;

FEMALE; HUMANS; OLIGONUCLEOTIDE PROBES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

HUMAN PAPILLOMAVIRUS;

EID: 73049114642     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2009.10.024     Document Type: Article

References (20)

1. Aho J., Hankins C., Tremblay C., Lang F., Forest P., Pourreaux K., Rouah F., Coutlée F., and The Canadian Women's HIV Study Group. Molecular analysis of human papillomavirus type 52 isolates detected in the genital tract of human immunodeficiency virus-seropositive and -seronegative women. J. Infect. Dis. 188 (2003) 1517-1527
2. Bosch F.X., Lorincz A., Muñoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55 (2002) 244-265
3. Calleja-Macias I.E., Villa L.L., Prado J.C., Kalantari M., Allan B., Williamson A.L., Chung L.P., Collins R.J., Zuna R.E., Dunn S.T., Chu T.Y., Cubie H.A., Cuschieri K., von Knebel-Doeberitz M., Martins C.R., Sanchez G.I., Bosch F.X., Munoz N., and Bernard H.U. Worldwide genomic diversity of the high-risk human papillomavirus types 31, 35, 52, and 58, four close relatives of human papillomavirus type 16. J. Virol. 79 (2005) 13630-13640
4. Clifford G.M., Smith J.S., Plummer M., Muñoz N., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88 (2003) 63-73
5. Coutlée F., Rouleau D., Ghattas G., Hankins C., Vézina S., Coté P., Macleod J., de Pokomandy A., Money D., Walmsley S., Voyer H., Brassard P., and Franco E. Confirmatory real-time PCR assay for human papillomavirus (HPV) type 52 infection in anogenital specimens screened for HPV infection with the linear array HPV genotyping test. J. Clin. Microbiol. 45 (2007) 3821-3823
6. Cuschieri K.S., and Cubie H.A. The role of human papillomavirus testing in cervical screening. J. Clin. Virol. 32 Suppl. 1 (2005) S34-S42
7. Evans M.F., Adamson C.S., Simmons-Arnold L., and Cooper K. Touchdown General Primer (GP5+/GP6+) PCR and optimized sample DNA concentration support the sensitive detection of human papillomavirus. BMC Clin. Pathol. 5 (2005) 10
8. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., Rush B.B., Glass A.G., and Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97 (2005) 1072-1079
9. Kocjan B.J., Poljak M., Seme K., Potočnik M., Fujs K., and Babič D.Z. Distribution of human papillomavirus genotypes in plucked eyebrow hairs from Slovenian males with genital warts. Infect. Genet. Evol. 5 (2005) 255-259
10. Kocjan B.J., Seme K., and Poljak M. Detection and differentiation of human papillomavirus genotypes HPV-6 and HPV-11 by FRET-based real-time PCR. J. Virol. Methods 153 (2008) 245-249
11. Kovanda A., Juvan U., Šterbenc A., Kocjan B.J., Seme K., Jančar N., Vrtačnik-Bokal E., and Poljak M. Pre-vaccination distribution of human papillomavirus (HPV) genotypes in women with cervical intraepithelial neoplasia grade 3 (CIN 3) lesions in Slovenia. Acta Dermatovenerol. Alp. Panonica Adriat. 18 (2009) 47-52
12. Marks M., Gupta S.B., Liaw K.L., Kim E., Tadesse A., Coutlee F., Sriplienchan S., Celentano D.D., and Gravitt P.E. Confirmation and quantitation of human papillomavirus type 52 by Roche Linear Array using HPV52-specific TaqMan E6/E7 quantitative real-time PCR. J. Virol. Methods 156 (2009) 152-156
13. Parkin D.M., Pisani P., and Ferlay J. Global cancer statistics. CA Cancer J. Clin. 49 (1999) 33-64
14. Raiol T., Wyant P.S., de Amorim R.M., Cerqueira D.M., Milanezi N.G., Brígido Mde M., Sichero L., and Martins C.R. Genetic variability and phylogeny of the high-risk HPV-31, -33, -35, -52, and -58 in central Brazil. J. Med. Virol. 81 (2009) 685-692
15. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., and Clifford G.M. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121 (2007) 621-632
16. Stevens M.P., Garland S.M., and Tabrizi S.N. Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler 480 system. J. Virol. Methods 147 (2008) 290-296
17. van Hamont D., Bekkers R.L., Massuger L.F., and Melchers W.J. Detection, management, and follow-up of pre-malignant cervical lesions and the role for human papillomavirus. Rev. Med. Virol. 18 (2008) 117-132
18. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., and Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 (1999) 12-19
19. Whelan J.A., Russell N.B., and Whelan M.A. A method for the absolute quantification of cDNA using real-time PCR. J. Immunol. Methods 278 (2003) 261-269
20. Woodman C.B., Collins S.I., and Young L.S. The natural history of cervical HPV infection: unresolved issues. Nat. Rev. Cancer 7 (2007) 11-22